Search

Search Constraints

You searched for: Author/Creator Botti, Claudio

Search Results

1. Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer. Issue 8 (August 2015)

2. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Issue 4 (3rd April 2018)

3. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. Issue 1 (December 2017)

4. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. (April 2013)

5. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence. Issue 11 (15th January 2020)

6. Modeling the positioning of single needle electrodes for the treatment of breast cancer in a clinical case. Issue 3 (December 2015)

7. Modeling the positioning of single needle electrodes for the treatment of breast cancer in a clinical case. Issue 3 (December 2015)

8. Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. Issue 11 (2nd June 2016)

10. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. (November 2021)